We want our innovations to have a purpose and improve the lives of people who need them, no matter where they live or their ability to pay.

Christophe Weber, President & CEO, Takeda

**Access to Medicines: Advancing Innovative Healthcare**

Takeda’s Access to Medicines (AtM) approach is an integral part of our commitment to improving the lives of patients around the world. Our initiatives are designed to address unmet medical needs and elevate standards of healthcare for patients suffering from serious diseases:

**Six therapeutic areas**: oncology, rare diseases, vaccines, plasma-derived therapies, gastroenterology, and neuroscience.

**Collaborating with policy makers and advocacy groups** to strengthen ecosystems and accelerate patient access.

**Addressing access barriers** in local health systems to provide high-quality patient care.

**Building innovative programs** that improve patient access to medicines and treatments.

Our Access to Medicines initiatives are recognised by experts in the industry.

**We are committed to achieving better health for a brighter future.**

---

There are 2 billion people around the world without proper access to medicines.

Our programmes have unlocked better care for millions of patients.

We want to support communities who are unable to access innovative medicines and quality treatment when faced with serious, complex, and rare diseases.

Interventions to support patients including disease awareness, patient care and support.

End-to-end access, from drug development to long-term patient care.

Our programmes have unlocked better care for millions of patients.

Our Access to Medicines initiatives are recognised by experts in the industry.

We want our innovations to have a purpose and improve the lives of people who need them, no matter where they live or their ability to pay.

Christophe Weber, President & CEO, Takeda